WO2003048720A2 - Computersystem und verfahren zur berechnung von adme-eigenschaften - Google Patents
Computersystem und verfahren zur berechnung von adme-eigenschaften Download PDFInfo
- Publication number
- WO2003048720A2 WO2003048720A2 PCT/EP2002/014150 EP0214150W WO03048720A2 WO 2003048720 A2 WO2003048720 A2 WO 2003048720A2 EP 0214150 W EP0214150 W EP 0214150W WO 03048720 A2 WO03048720 A2 WO 03048720A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substance
- properties
- adme
- database
- molecular properties
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/30—Prediction of properties of chemical compounds, compositions or mixtures
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/40—Searching chemical structures or physicochemical data
Definitions
- the invention relates to a computer system and a method for calculating ADME properties of a substance, in particular for a substance with a pharmacological effect or a substance for crop protection applications.
- the effectiveness of active substances is determined by their interaction with the molecular, biological target, as well as by the concentration at the target location. Both parameters are usually determined by different molecular parameters and can therefore be optimized independently of one another within certain limits. While the intrinsic biochemical effect can be determined in in-vitro tests at a very early stage of research for large numbers of substances, the concentration in the site of action can only be investigated by experiments on the whole organism (animal, plant or fungus). The latter means that due to the complexity of the tests, the information can only be carried out in late research stages and is therefore not available for the first optimization cycles.
- ADME behavior absorption, distribution, metabolism, excretion
- Typical properties that are usually taken into account are e.g. B.
- the assessment of the substances is then usually carried out by observing certain limits, which are usually obtained from empirical values or from the statistical distribution of properties for commercial products [CA Lipinski, F. Lombardo, BW Dominy, PJ Feeney, Adv.
- a computer program product for at least partially automatic calculation of molecular sizes based on a substance library is known from US Pat. No. 5,901,069. However, this method does not allow the calculation of ADME properties.
- the invention is based on the object of providing an improved method for calculating an ADME property of a substance and a corresponding computer program and computer system.
- the object on which the invention is based is achieved in each case with the features of the independent patent claims.
- the invention can advantageously be used both for already synthesized substances and for “virtual structures” of substance libraries.
- biophysical relationships between the molecular and physicochemical properties of the substances and the ADME properties under consideration are used to calculate the ADME properties
- the mathematical description is then made either using an analytical formula or, in the case of more complex relationships, using a numerical simulation.
- Biophysical model in which the molecular properties are entered as input variables.
- the biophysical model establishes a connection between these molecular properties and the ADME property or properties. In this way, one obtains an immediate statement about the ADME properties and not just about correlated surrogate sizes, as is the case in the prior art.
- lipophilicity, binding to proteins and molecular size are used as molecular properties. For example, this allows modeling the absorption of active substances in a human, animal or plant organism. Lipophilicity is determined by distribution coefficients between a lipoid phase (eg octanol, cooking oil, hexane, phospholipid membranes) and Described water. For example, the molecular weight or the molar volume can serve as a measure of the molecular size.
- a lipoid phase eg octanol, cooking oil, hexane, phospholipid membranes
- the molecular weight or the molar volume can serve as a measure of the molecular size.
- the invention allows direct conclusions to be drawn from the molecular properties of the ADME properties, so that a calculation with improved accuracy is possible.
- the biophysical model is a physiologically based pharmacokinetic model.
- the model For the investigation of the ADME properties of a substance, for example in the human body, the model at least includes those for
- Mass conservation equations expressed in the form of a system of differential equations the input variables of the system of differential equations being obtained directly from the calculated molecular properties.
- the chemical structure can also be represented, for example, in the form of a descriptor or a so-called fingerprint.
- the chemical structure can be entered decentrally from a client computer.
- the client computer is located, for example, directly at a chemist's workplace for entering new chemical structures for which the ADME properties are to be predetermined.
- This database is then queried cyclically, for example by a server computer. Once the new chemical structure is entered by the
- the server computer can access a further database in which experimentally determined molecular properties of the substance are stored. After determining the molecular properties, these are incorporated into the biophysical model by another. Entered the program call so that the desired ADME properties are calculated automatically.
- This process is preferably carried out repeatedly for different substances, for example the same chemical base body.
- the results of the ADME calculations are then output in a structured form, for example sorted according to the value of a specific ADME property or sorted according to a weighted index of ADME properties.
- a statistical method for calculating the molecular properties from the chemical structure is used, such as a QSAR or HQSAR method, or a method based on a neural network.
- a QSAR or HQSAR method or a method based on a neural network.
- the invention in particular enables the following ADME properties to be calculated:
- fraction of a dose absorbed after oral application fraction absorbed
- the invention in particular enables the calculation of the following ADME properties:
- the calculated data are either stored directly in a database or output in a table.
- the data available in this way form the basis for a
- Evaluation is carried out manually using suitable data evaluation and visualization software.
- the substances or structures that are in the optimal distribution of properties are searched for by ranking (e.g. the 10 substances with the highest absorption after oral application). If more than one property is taken into account in the ranking, an index can be calculated that includes this (in the simplest case, the sum of the values of all sizes), and the properties can be weighted according to relevance.
- FIG. 1 shows a flow diagram for calculating ADME properties from the molecular properties of a substance
- Figure 2 shows an embodiment of a biophysical model for
- FIG. 3 shows a table for calculating organ / blood distribution coefficients for the model in FIG. 2,
- Figure 4 shows an embodiment of a computer system according to the invention.
- FIG. 1 shows a flow chart for the calculation of ADME properties of a substance.
- step 1 the molecular property of a substance is determined. This can be done experimentally if the substance has already been synthesized. Furthermore, the molecular properties can also be determined by means of a calculation.
- step 1 it is possible to access both experimentally determined molecular properties and molecular properties of the substance determined by calculation. This way you can Supplement experimental methods with the calculation methods for determining the molecular properties.
- the molecular properties of the substance determined in step 1 are entered in a biophysical model in step 2.
- Model establishes a connection between the molecular sizes and the ADME properties of interest.
- This can be, for example, a physiologically based pharmaco-kinetic model.
- An embodiment of such a biophysical model is explained in more detail below with reference to FIGS. 2 and 3.
- step 3 the ADME properties are output from the biophysical model. It is particularly advantageous here that the ADME properties are determined directly from the molecular properties, without the interposition of surrogate variables that require interpretation. This allows a fully automatic process for the calculation of the ADME properties.
- FIG. 2 shows a biophysical model 4 of a warm-blooded animal, for example a human.
- the biophysical model 4 contains a number of partial
- Models for those organs that are most relevant for the distribution of the substance in the body are partial model 5 for the lungs, partial model 6 for the liver, partial model 7 for the kidneys and partial models 8 for various other organs X.
- the partial models 5, 1, 8 are "interconnected” by venous blood 9 and arterial blood 10.
- the venous blood 9 enters the partial model 5 for the lungs, where it is converted into arterial blood 10.
- the arterial Blood 10 then passes into the further sub-models 6, 1 and 8, from where it emerges again as venous blood 9.
- the various sub-models of the organs are thus rendered venous
- biophysical model 4 contains an excretion model 11 for the sub-models 6 and 7, that is to say for the liver and the kidneys.
- the biophysical model is provided for modeling the temporal concentration distribution of a dose of the substance to be examined.
- the dose is supplied via the venous blood 9, that is to say, for example via the portal vein after oral administration or by injection into a vein.
- a corresponding table of empirical values can be accessed for the flow rate Qu me of venous blood 9 through the lungs 5. Also, for the flow rate of arterial blood 10 through the other body part models 6, 7, 8 corresponding empirical values for the flow rates of O - he b, n e and r Que Qx be accessed.
- the quantities C x are the concentration of the substance in the organ X in question at a specific point in time.
- the parameter K x denotes the distribution coefficient of the substance between the blood and the organ X in the state of equilibrium.
- the parameters CL e er and CLNieren denote the intrinsic excretion of the liver and kidneys.
- V - 0 - C - O • ⁇ -
- the parameter f u is calculated from the reciprocal of the distribution coefficient of the substance in the equilibrium between blood plasma and water.
- Vj volume of the kidneys
- C ar concentration of the substance that reaches the kidneys through the arterial blood
- Kw partition coefficient of the substance between blood and kidneys in the
- CL k intravenously added dose of the substance.
- the term depends on Lipophilicity value of the substance can also be determined from a molecular property.
- V ve volume of venous blood
- K x distribution coefficient of the substance between blood and organ X in the state of equilibrium
- Ciu concentration of the substance in the lungs
- Ki u distribution coefficient of the substance in the balance between blood and lungs
- Dose dose of the substance that is added to the venous blood over time t according to an input function I (t).
- the distribution coefficients for a substance in the equilibrium between fat and water (K fat ) and between protein and water (Kp ro t e in) can be determined by calculation.
- the distribution coefficients mentioned are determined either by calculation or experimentally; There are methods known per se from the prior art for the computational as well as the experimental determination.
- organ compositions of water, fat and protein are used for the calculation. These can be determined from the table in FIG. 3.
- the table in FIG. 3 shows the total mass of the organ in question and the absolute proportions in grams of water, fat and protein in the organ for various organs.
- F aster total mass of water in the organ / total mass of the organ
- F fat total mass of fat in the organ / total mass of the organ
- Fprotein total mass of protein in the organ / total mass of the organ
- K ⁇ rgan / water F aster + KFett ' FFett + Kp ro tein ' Fp ro tem (1)
- the organ / blood or organ / plasma can be derived from this
- the coefficients Kßiut / water and Kp ⁇ asm a / water are also calculated according to formula (1).
- FIG. 4 shows a block diagram of a computer system for the calculation of ADME properties of a substance.
- a file 12 contains the chemical structure of the substance, for example in the form of a so-called descriptor or a fingerprint.
- File 12 is manually entered by a chemist or is part of one
- the file 12 is entered into a database 13.
- the database 13 is used to store files 12 describing chemical structures.
- the file 13 is queried cyclically by a program 14, specifically to determine whether a new file 12 has been entered in the period between the previous query.
- the file 12 can be entered from a client computer.
- the database 13 is located on, for example Server computer and also the program 14, which polls the database 13 cyclically.
- a distributed system can be implemented in this way.
- the molecular properties calculated by the program 15 are temporarily stored in a file or stored in a database 16.
- the program 15 After completion of the calculation of the molecular properties and their storage in the database 16, the program 15 automatically starts a program 17 for the calculation of one or more ADME properties of the substance.
- the program 17 accesses the database 16 in order to call up the molecular properties of the substance previously calculated by the program 15.
- the program 17 accesses a database 18, which contains further experimentally determined molecular properties of the substance. This assumes that the substance has been previously synthesized in order to experimentally determine the molecular properties of the substance in a file 19 in the database
- the ADME properties calculated by the program 17 based on the molecular properties stored in the database 16 and / or the database 18 are stored in a database 20.
- a program 21 accesses the database 20 in order to generate a structured output. This can be done in the form of a table in the form of a spread sheet. The output can also be sorted according to certain ADME properties.
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/497,759 US7765092B2 (en) | 2001-12-07 | 2002-11-25 | Computer system and method for calculating ADME properties |
AU2002346846A AU2002346846A1 (en) | 2001-12-07 | 2002-11-25 | Computer system and method for calculating adme properties |
JP2003549866A JP2005512176A (ja) | 2001-12-07 | 2002-11-25 | アドメ特性を計算するコンピュータシステムおよび方法 |
CA002469388A CA2469388A1 (en) | 2001-12-07 | 2002-11-25 | Computer system and method for calculating adme properties |
EP02783091A EP1456646A2 (de) | 2001-12-07 | 2002-11-25 | Computersystem und verfahren zur berechnung von adme-eigenschaften |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10160270.7 | 2001-12-07 | ||
DE10160270A DE10160270A1 (de) | 2001-12-07 | 2001-12-07 | Computersystem und Verfahren zur Berechnung von ADME-Eigenschaften |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003048720A2 true WO2003048720A2 (de) | 2003-06-12 |
WO2003048720A3 WO2003048720A3 (de) | 2004-04-22 |
Family
ID=7708460
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2002/014150 WO2003048720A2 (de) | 2001-12-07 | 2002-11-25 | Computersystem und verfahren zur berechnung von adme-eigenschaften |
Country Status (9)
Country | Link |
---|---|
US (1) | US7765092B2 (de) |
EP (1) | EP1456646A2 (de) |
JP (1) | JP2005512176A (de) |
CN (1) | CN1659435A (de) |
AU (1) | AU2002346846A1 (de) |
CA (1) | CA2469388A1 (de) |
DE (1) | DE10160270A1 (de) |
RU (1) | RU2004120787A (de) |
WO (1) | WO2003048720A2 (de) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007510206A (ja) * | 2003-10-29 | 2007-04-19 | バイエル・テクノロジー・サービシーズ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 化学物質のadme特性を視覚化するための方法 |
US7539607B2 (en) * | 2002-12-03 | 2009-05-26 | Bayer Technology Services Gmbh | Computer system and method of calculating a pharmacokinetic behavior of a chemical substance in insects |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102004010516A1 (de) | 2004-03-04 | 2005-09-22 | Bayer Technology Services Gmbh | Verbessertes Verfahren zur zeitlichen Dosierung von Arzneistoffen |
WO2006065950A2 (en) * | 2004-12-16 | 2006-06-22 | Pharmix Corporation | Modeling biological effects of molecules using molecular property models |
DE102005028080A1 (de) | 2005-06-17 | 2006-12-21 | Bayer Technology Services Gmbh | Verfahren zur zeitlich gesteuerten intravenösen Verabreichung des Narkosemittels Propofol |
US8380730B2 (en) * | 2008-10-09 | 2013-02-19 | International Business Machines Corporation | Program invocation from a query interface to parallel computing system |
DE102010060311B3 (de) * | 2010-11-02 | 2012-02-02 | Freie Universität Berlin | Verfahren zur Unterstützung klinischer Studien |
EP3236956A1 (de) | 2014-12-23 | 2017-11-01 | Bosteels, Arnaud | Kombination von remifentanil und propofol |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5751605A (en) * | 1996-08-15 | 1998-05-12 | Tripos, Inc. | Molecular hologram QSAR |
WO2000015178A2 (en) * | 1998-09-14 | 2000-03-23 | Navicyte, Inc. | Computer implemented pharmacokinetics method and program |
WO2000079268A2 (en) * | 1999-06-18 | 2000-12-28 | Biacore Ab | Method and apparatus for assaying a drug candidate to estimate a pharmacokinetic parameter associated therewith |
EP1167969A2 (de) * | 2000-06-14 | 2002-01-02 | Pfizer Inc. | Verfahren und System zur Voraussage von pharmakokinetischen Eigenschaften |
WO2002010742A2 (en) * | 2000-07-28 | 2002-02-07 | Lion Bioscience Ag | System and method for predicting adme/tox characteristics of a compound |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002010741A2 (en) * | 2000-07-28 | 2002-02-07 | Lion Bioscience Ag | Regional intestinal permeability model |
US20020169561A1 (en) * | 2001-01-26 | 2002-11-14 | Benight Albert S. | Modular computational models for predicting the pharmaceutical properties of chemical compunds |
-
2001
- 2001-12-07 DE DE10160270A patent/DE10160270A1/de not_active Ceased
-
2002
- 2002-11-25 CN CN028278100A patent/CN1659435A/zh active Pending
- 2002-11-25 EP EP02783091A patent/EP1456646A2/de not_active Withdrawn
- 2002-11-25 RU RU2004120787/15A patent/RU2004120787A/ru not_active Application Discontinuation
- 2002-11-25 AU AU2002346846A patent/AU2002346846A1/en not_active Abandoned
- 2002-11-25 CA CA002469388A patent/CA2469388A1/en not_active Abandoned
- 2002-11-25 WO PCT/EP2002/014150 patent/WO2003048720A2/de not_active Application Discontinuation
- 2002-11-25 US US10/497,759 patent/US7765092B2/en not_active Expired - Fee Related
- 2002-11-25 JP JP2003549866A patent/JP2005512176A/ja active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5751605A (en) * | 1996-08-15 | 1998-05-12 | Tripos, Inc. | Molecular hologram QSAR |
WO2000015178A2 (en) * | 1998-09-14 | 2000-03-23 | Navicyte, Inc. | Computer implemented pharmacokinetics method and program |
WO2000079268A2 (en) * | 1999-06-18 | 2000-12-28 | Biacore Ab | Method and apparatus for assaying a drug candidate to estimate a pharmacokinetic parameter associated therewith |
EP1167969A2 (de) * | 2000-06-14 | 2002-01-02 | Pfizer Inc. | Verfahren und System zur Voraussage von pharmakokinetischen Eigenschaften |
WO2002010742A2 (en) * | 2000-07-28 | 2002-02-07 | Lion Bioscience Ag | System and method for predicting adme/tox characteristics of a compound |
Non-Patent Citations (1)
Title |
---|
NORRIS D A ET AL: "Development of predictive pharmacokinetic simulation models for drug discovery" JOURNAL OF CONTROLLED RELEASE, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, Bd. 65, Nr. 1-2, M{rz 2000 (2000-03), Seiten 55-62, XP004190311 ISSN: 0168-3659 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7539607B2 (en) * | 2002-12-03 | 2009-05-26 | Bayer Technology Services Gmbh | Computer system and method of calculating a pharmacokinetic behavior of a chemical substance in insects |
JP2007510206A (ja) * | 2003-10-29 | 2007-04-19 | バイエル・テクノロジー・サービシーズ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 化学物質のadme特性を視覚化するための方法 |
Also Published As
Publication number | Publication date |
---|---|
JP2005512176A (ja) | 2005-04-28 |
US20050119832A1 (en) | 2005-06-02 |
US7765092B2 (en) | 2010-07-27 |
CN1659435A (zh) | 2005-08-24 |
DE10160270A1 (de) | 2003-06-26 |
RU2004120787A (ru) | 2005-04-10 |
WO2003048720A3 (de) | 2004-04-22 |
EP1456646A2 (de) | 2004-09-15 |
CA2469388A1 (en) | 2003-06-12 |
AU2002346846A1 (en) | 2003-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1671251B1 (de) | Verfahren zur simulation der wechselwirkung von chemischen substanzen mit lebenden organismen | |
DE60037116T2 (de) | System zur behandlung eines patienten mit einem medikament zur optimierung der therapie und zur verhinderung eines negativen nebeneffektes | |
WO2003048720A2 (de) | Computersystem und verfahren zur berechnung von adme-eigenschaften | |
DE602004010154T2 (de) | Verfahren zur bestimmung der auswirkung eines aus mehreren komponenten bestehenden naturproduktgemischs auf das biologische profil einer krankheit in einer gruppe lebender systeme sowie entwicklung und qualitätskontrolle von medizin auf naturproduktbasis | |
WO2021165386A1 (de) | Vorhersage von formulierungseigenschaften | |
DE102018207557A1 (de) | Bestimmung eines Dehnungsgrades von Haar mit einem NIR-Sensor | |
EP1426763B1 (de) | Computersystem und Verfahren zur Berechnung eines pharmakokinetischen Verhaltens einer chemischen Substanz in Insekten | |
DE10350525A1 (de) | Verfahren zur Visualisierung der ADME-Eigenschaften chemischer Substanzen | |
DE102018207558A1 (de) | Ermitteln von äußeren Schäden von Haaren | |
LU102506A1 (de) | Ein Verfahren, ein System, ein Speichermedium und Programm zum Detektieren der Aromastilmerkmale des rauchgehärteten Tabaks | |
Flache et al. | Multi-Agenten-Modelle | |
DE2919517C2 (de) | ||
EP1451750B1 (de) | Verfahren zur identifikation von pharmakophoren | |
Holländer et al. | Current reference values of organ weights and indices for forensic practice, part 1: Brain and heart | |
DE19781642B4 (de) | Verfahren zum Bestimmen eines die maximale Sauerstoffaufnahme beschreibenden Wertes eines zu beurteilenden Lebenswesens | |
Wilde et al. | Pilot study on quality assurance in cardiac surgery | |
Utschig | Analysis of Single Tree Productivity and Growing Space on Long Term Trial Plots–Methods, Program Development and Initial Results– | |
DE10233022A1 (de) | Verfahren und Anlage zur Lösung von Aufgaben der adaptiven Chemie | |
EP0598741B1 (de) | Verfahren zum generieren eines referenzstrings | |
WO1994007197A1 (de) | Verfahren zur bearbeitung eines anwenderprogramms auf einem parallelrechnersystem | |
EP4168970A1 (de) | Verfahren zur bestimmung individueller pflegemittelformulierungen | |
Schmidt et al. | Chronic pain patient’s acceptance and satisfaction with their analgesic medication: Development and validation of the QAMPAS questionnaire | |
DE102005029437B4 (de) | Verfahren und Vorrichtung zum computergestützten Auffinden von ähnlichen Molekülen | |
Meister | Evaluation verschiedener Imputationsverfahren zur Aufbereitung großer Datenbestände am Beispiel der SrV-Studie von 2013 | |
Gyimesi et al. | HASH (0x556da14d4e68) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002783091 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1447/DELNP/2004 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002346846 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2469388 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003549866 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004120787 Country of ref document: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20028278100 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2002783091 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10497759 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002783091 Country of ref document: EP |